-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Allan Gibofsky, MD, JD

Articles by Allan Gibofsky, MD, JD

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Biosimilar medicines: what are they and how are they used?

ByVibeke Strand, MD,Colby Evans, MD,Allan Gibofsky, MD, JD

November 1st 2022

Plain Language Summary

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

What do patients and health care providers still need to know about biosimilar medicines?

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

ByAllan Gibofsky, MD, JD,Colby Evans, MD,Vibeke Strand, MD

November 1st 2022

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

What are the current challenges to wider biosimilar use in the United States?

ByColby Evans, MD,Allan Gibofsky, MD, JD,Vibeke Strand, MD

November 1st 2022

Plain Language Summary

Current Therapeutic Agents and Treatment Paradigms for the Management of Rheumatoid Arthritis

ByAllan Gibofsky, MD, JD

May 31st 2014

Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis: A Synopsis

ByAllan Gibofsky, MD, JD

May 31st 2014

Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis

ByAllan Gibofsky, MD, JD

December 24th 2012

Comparative Effectiveness of Current Treatments for Rheumatoid Arthritis

ByAllan Gibofsky, MD, JD

December 24th 2012

Latest Updated Articles

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective
November 1st 2022
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
November 1st 2022
Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys
November 1st 2022
Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis
December 24th 2012
Comparative Effectiveness of Current Treatments for Rheumatoid Arthritis
December 24th 2012
Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis: A Synopsis
May 31st 2014

Trending on AJMC

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?

FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Online GLP-1 Sellers Often Skip Clinician Oversight